Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections

Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowin...

Full description

Saved in:
Bibliographic Details
Published inAdvanced materials (Weinheim) Vol. 36; no. 46; pp. e2406348 - n/a
Main Authors Joseph, John, Baby, Helna Mary, Quintero, Joselyn Rojas, Kenney, Devin, Mebratu, Yohannes A, Bhatia, Eshant, Shah, Purna, Swain, Kabir, Lee, Dongtak, Kaur, Shahdeep, Li, Xiang‐Ling, Mwangi, John, Snapper, Olivia, Nair, Remya, Agus, Eli, Ranganathan, Sruthi, Kage, Julian, Gao, Jingjing, Luo, James N, Yu, Anthony, Park, Dongsung, Douam, Florian, Tesfaigzi, Yohannes, Karp, Jeffrey M, Joshi, Nitin
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.11.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections. A pathogen capture and neutralizing spray (PCANS) is reported to prevent respiratory infections through a multi‐modal approach. PCANS coats the nasal cavity, capturing large respiratory droplets and serving as a physical barrier against viruses and bacteria, while neutralizing them with over 99.99% effectiveness. In mice, PCANS shows nasal retention for ≈8 hours and offers pre‐exposure protection against lethal viral infections.
AbstractList Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections.
Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of action-either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi-modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre-exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily-use prophylactic against respiratory infections.Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of action-either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi-modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre-exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily-use prophylactic against respiratory infections.
Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of action—either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi‐modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi‐modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre‐exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily‐use prophylactic against respiratory infections. A pathogen capture and neutralizing spray (PCANS) is reported to prevent respiratory infections through a multi‐modal approach. PCANS coats the nasal cavity, capturing large respiratory droplets and serving as a physical barrier against viruses and bacteria, while neutralizing them with over 99.99% effectiveness. In mice, PCANS shows nasal retention for ≈8 hours and offers pre‐exposure protection against lethal viral infections.
Author Agus, Eli
Kaur, Shahdeep
Mwangi, John
Joseph, John
Mebratu, Yohannes A
Joshi, Nitin
Karp, Jeffrey M
Baby, Helna Mary
Yu, Anthony
Li, Xiang‐Ling
Swain, Kabir
Snapper, Olivia
Bhatia, Eshant
Ranganathan, Sruthi
Tesfaigzi, Yohannes
Quintero, Joselyn Rojas
Nair, Remya
Kenney, Devin
Gao, Jingjing
Lee, Dongtak
Park, Dongsung
Douam, Florian
Kage, Julian
Luo, James N
Shah, Purna
Author_xml – sequence: 1
  givenname: John
  surname: Joseph
  fullname: Joseph, John
  organization: Harvard Medical School
– sequence: 2
  givenname: Helna Mary
  surname: Baby
  fullname: Baby, Helna Mary
  organization: Brigham and Women's Hospital
– sequence: 3
  givenname: Joselyn Rojas
  surname: Quintero
  fullname: Quintero, Joselyn Rojas
  organization: Brigham and Women's Hospital
– sequence: 4
  givenname: Devin
  surname: Kenney
  fullname: Kenney, Devin
  organization: Chobanian & Avedisian School of Medicine
– sequence: 5
  givenname: Yohannes A
  surname: Mebratu
  fullname: Mebratu, Yohannes A
  organization: Brigham and Women's Hospital
– sequence: 6
  givenname: Eshant
  surname: Bhatia
  fullname: Bhatia, Eshant
  organization: Indian Institute of Technology
– sequence: 7
  givenname: Purna
  surname: Shah
  fullname: Shah, Purna
  organization: Brigham and Women's Hospital
– sequence: 8
  givenname: Kabir
  surname: Swain
  fullname: Swain, Kabir
  organization: Brigham and Women's Hospital
– sequence: 9
  givenname: Dongtak
  surname: Lee
  fullname: Lee, Dongtak
  organization: Harvard Medical School
– sequence: 10
  givenname: Shahdeep
  surname: Kaur
  fullname: Kaur, Shahdeep
  organization: Harvard Medical School
– sequence: 11
  givenname: Xiang‐Ling
  surname: Li
  fullname: Li, Xiang‐Ling
  organization: Brigham and Women's Hospital
– sequence: 12
  givenname: John
  surname: Mwangi
  fullname: Mwangi, John
  organization: Brigham and Women's Hospital
– sequence: 13
  givenname: Olivia
  surname: Snapper
  fullname: Snapper, Olivia
  organization: Brigham and Women's Hospital
– sequence: 14
  givenname: Remya
  surname: Nair
  fullname: Nair, Remya
  organization: Harvard Medical School
– sequence: 15
  givenname: Eli
  surname: Agus
  fullname: Agus, Eli
  organization: Brigham and Women's Hospital
– sequence: 16
  givenname: Sruthi
  surname: Ranganathan
  fullname: Ranganathan, Sruthi
  organization: Brigham and Women's Hospital
– sequence: 17
  givenname: Julian
  surname: Kage
  fullname: Kage, Julian
  organization: Brigham and Women's Hospital
– sequence: 18
  givenname: Jingjing
  surname: Gao
  fullname: Gao, Jingjing
  organization: Harvard Medical School
– sequence: 19
  givenname: James N
  surname: Luo
  fullname: Luo, James N
  organization: Brigham and Women's Hospital
– sequence: 20
  givenname: Anthony
  surname: Yu
  fullname: Yu, Anthony
  organization: Harvard Medical School
– sequence: 21
  givenname: Dongsung
  surname: Park
  fullname: Park, Dongsung
  organization: Brookhaven National Laboratory
– sequence: 22
  givenname: Florian
  surname: Douam
  fullname: Douam, Florian
  organization: Chobanian & Avedisian School of Medicine
– sequence: 23
  givenname: Yohannes
  surname: Tesfaigzi
  fullname: Tesfaigzi, Yohannes
  email: ytesfaigzi@bwh.harvard.edu
  organization: Brigham and Women's Hospital
– sequence: 24
  givenname: Jeffrey M
  surname: Karp
  fullname: Karp, Jeffrey M
  email: jmkarp@bwh.harvard.edu
  organization: Harvard Stem Cell Institute
– sequence: 25
  givenname: Nitin
  orcidid: 0000-0001-8138-7611
  surname: Joshi
  fullname: Joshi, Nitin
  email: njoshi@bwh.harvard.edu
  organization: Harvard Medical School
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39318086$$D View this record in MEDLINE/PubMed
BookMark eNqF0btuFDEUBmALBZFNoKVEI9HQzMa3GdvlKuESKUtQEgqq0YkvyJFnPNgzRNPxCDwjT4KjTYJEk8Yu_P3W0fkP0N4QB4vQa4LXBGN6BKaHNcWU45Zx-QytSENJzbFq9tAKK9bUquVyHx3kfIMxVi1uX6B9phiRWLYr9O0q3kIyFVQXYLyGEJbq0vdjsNV2DpP_8-v3NhoI1WfI5bwcEyyVi6n6kuxPO0x--F5d2Dz6BFNMS3U6OKsnH4f8Ej13ELJ9dX8foq8f3l8df6rPzj-eHm_Oas2olLVjTAvBgDRYUq6Eo9emEdwp0EYIxQwBqp0GbLTSoFvnOFWCNYIIW94EO0Tvdv-OKf6YbZ663mdtQ4DBxjl3jGDFKZEEF_r2P3oT5zSU6YqikpcRMC3qzb2ar3trujH5HtLSPSytgPUO6BRzTtY9EoK7u1a6u1a6x1ZKQO0Ctz7Y5QndbU62m3_ZvzL3kEo
Cites_doi 10.3109/10717544.2013.849778
10.1038/s41591-021-01301-0
10.1172/JCI148517
10.1371/journal.pone.0237480
10.1002/med.21941
10.3390/polym12020329
10.1136/bmjopen-2021-059661
10.1002/advs.202003895
10.1134/S207997802003005X
10.1038/s41586-021-04389-z
10.1038/s41421-022-00510-2
10.1016/j.ijpharm.2010.09.028
10.1016/B978-0-8155-2025-2.10010-1
10.1038/s41591-020-0868-6
10.3389/fmedt.2021.687681
10.1038/s41579-018-0001-8
10.1080/03639040802149046
10.1016/j.jcv.2022.105248
10.1038/s41563-023-01475-7
10.1371/journal.pone.0014320
10.1016/j.celrep.2020.108062
10.1002/adma.202008304
10.3390/pharmaceutics14030530
10.1016/j.supflu.2022.105762
10.1038/s41598-021-99765-0
10.1371/journal.ppat.1008098
10.1371/journal.ppat.1004089
10.1084/jem.89.1.11
10.3934/biophy.2021008
10.1111/j.2042-7158.1987.tb03142.x
10.1186/s12890-020-01187-7
10.3390/ijms241512132
10.1371/journal.pone.0040422
10.1093/cid/ciac448
10.1081/DDC-100101325
10.1007/978-1-4939-6591-5_2
10.2147/IJGM.S328486
10.1016/j.cell.2020.05.042
10.1248/bpb.b14-00398
10.1080/14760584.2021.1915140
10.1111/j.2042-7158.1996.tb03929.x
10.3390/ijms222413202
10.1073/pnas.2202069119
10.1002/jbm.a.34851
10.1128/JVI.00159-10
10.1016/j.otohns.2003.07.005
10.1016/j.virol.2015.02.041
10.3390/immuno2040036
10.1001/jama.2020.8946
10.1016/j.lansea.2022.100036
10.1371/journal.pone.0021207
10.1016/S1473-3099(22)00320-6
10.1001/jamaoto.2020.3053
10.1056/NEJMoa2107058
10.1186/s12989-020-0339-8
10.1002/lary.29935
10.1002/EXP.20210038
10.1126/sciimmunol.abl9929
10.1007/978-1-4614-7978-9_5
10.1001/jamanetworkopen.2022.6108
10.1152/ajplung.00552.2020
10.1038/s43246-021-00153-y
10.1016/j.cegh.2021.100826
10.4168/aair.2019.11.3.306
10.1038/s41586-021-03673-2
10.1016/j.carres.2014.02.018
10.3389/fbioe.2020.581995
10.1021/acs.jpcc.7b03885
10.1513/AnnalsATS.201311-405PS
10.1016/j.xphs.2015.12.016
10.1016/j.apm.2022.08.008
10.1016/j.ejpb.2007.01.010
10.1002/viw2.16
10.1016/j.resp.2008.05.018
10.1038/ni1001-907
ContentType Journal Article
Copyright 2024 Wiley‐VCH GmbH
2024 Wiley‐VCH GmbH.
Copyright_xml – notice: 2024 Wiley‐VCH GmbH
– notice: 2024 Wiley‐VCH GmbH.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7SR
8BQ
8FD
JG9
7X8
DOI 10.1002/adma.202406348
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Engineered Materials Abstracts
METADEX
Technology Research Database
Materials Research Database
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Materials Research Database
Engineered Materials Abstracts
Technology Research Database
METADEX
MEDLINE - Academic
DatabaseTitleList Materials Research Database
CrossRef
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1521-4095
EndPage n/a
ExternalDocumentID 39318086
10_1002_adma_202406348
ADMA202406348
Genre article
Journal Article
GrantInformation_xml – fundername: Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital
– fundername: Fulbright Nehru Postdoctoral Fellowship
– fundername: Gillian Reny Stepping Strong Center for Trauma Innovation at the Brigham and Women's Hospital
– fundername: Boston University
– fundername: Peter Paul Career Development Award
– fundername: NIAID NIH HHS
  grantid: R01 AI148180
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
23M
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANLZ
AAONW
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABPVW
ACAHQ
ACCFJ
ACCZN
ACGFS
ACIWK
ACPOU
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
EBS
F00
F01
F04
F5P
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
Q.N
Q11
QB0
QRW
R.K
RNS
ROL
RWI
RWM
RX1
RYL
SUPJJ
TN5
UB1
UPT
V2E
W8V
W99
WBKPD
WFSAM
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WXSBR
WYISQ
XG1
XPP
XV2
YR2
ZZTAW
~02
~IA
~WT
.Y3
31~
6TJ
8WZ
A6W
AANHP
AASGY
AAYOK
AAYXX
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADMLS
ADNMO
AETEA
AEYWJ
AFFNX
AGHNM
AGQPQ
AGYGG
ASPBG
AVWKF
AZFZN
CITATION
EJD
FEDTE
FOJGT
HF~
HVGLF
LW6
M6K
NDZJH
PALCI
RIWAO
RJQFR
SAMSI
WTY
ZY4
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7SR
8BQ
8FD
JG9
7X8
ID FETCH-LOGICAL-c3288-f33c773a15082497f2bd574f9acd7793d1a2cfca0dc9cac6ff429735717ed1a73
IEDL.DBID DR2
ISSN 0935-9648
1521-4095
IngestDate Thu Jul 10 18:32:27 EDT 2025
Sat Jul 26 00:07:30 EDT 2025
Mon Jul 21 06:02:07 EDT 2025
Tue Jul 01 00:54:56 EDT 2025
Wed Jan 22 17:14:58 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 46
Keywords pathogen capture
virus neutralization
broad spectrum protection
nasal spray
antiviral
nasal prophylaxis
antibacterial
respiratory infections
Language English
License 2024 Wiley‐VCH GmbH.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3288-f33c773a15082497f2bd574f9acd7793d1a2cfca0dc9cac6ff429735717ed1a73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8138-7611
PMID 39318086
PQID 3128450802
PQPubID 2045203
PageCount 20
ParticipantIDs proquest_miscellaneous_3109421810
proquest_journals_3128450802
pubmed_primary_39318086
crossref_primary_10_1002_adma_202406348
wiley_primary_10_1002_adma_202406348_ADMA202406348
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-01
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle Advanced materials (Weinheim)
PublicationTitleAlternate Adv Mater
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2023; 76
2021; 27
2022; 132
2021; 20
2015; 38
2021; 22
2020; 20
2019; 11
2023; 9
2019; 15
2020; 17
2008; 34
2016; 105
2020; 12
2020; 323
2021; 320
2020; 11
2022; 22
2020; 10
2013; 6
1987; 39
2014; 21
2020; 8
2023; 24
2023; 22
2021; 33
2020; 1
2004; 130
2021; 595
2017; 121
2010; 5
2022; 602
2007; 67
2014; 11
2014; 10
2022; 155
2021; 8
2022; 112
2015; 481
2021; 3
2021; 2
2022; 191
2012
2017; 1522
2000; 26
2010; 402
2010
2020; 182
2020; 146
2021; 385
2020; 32
2022; 119
2011; 6
2008; 163
2010; 84
2021; 14
2023; 43
1990; 2
2021; 16
1949; 89
2021; 12
2021; 11
2022; 3
2022
2022; 5
2020
2022; 7
2022; 12
2020; 26
2022; 14
2021; 373
2021; 131
2001; 2
2022; 2
2012; 7
1996; 48
2018; 16
2014; 388
2014; 102
e_1_2_10_23_1
e_1_2_10_46_1
e_1_2_10_69_1
e_1_2_10_21_1
e_1_2_10_44_1
e_1_2_10_42_1
e_1_2_10_40_1
e_1_2_10_70_1
e_1_2_10_2_1
e_1_2_10_72_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_74_1
e_1_2_10_53_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_55_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_57_1
e_1_2_10_78_1
e_1_2_10_58_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_11_1
e_1_2_10_32_1
Wang C. C. (e_1_2_10_8_1) 2021; 373
e_1_2_10_30_1
e_1_2_10_51_1
Gizurarson S. (e_1_2_10_76_1) 1990; 2
Cannon M. L. (e_1_2_10_66_1) 2020
e_1_2_10_82_1
e_1_2_10_61_1
Xie X. (e_1_2_10_80_1) 2020; 11
e_1_2_10_84_1
e_1_2_10_29_1
e_1_2_10_63_1
Gaffar A. (e_1_2_10_26_1) 2022
e_1_2_10_65_1
e_1_2_10_25_1
e_1_2_10_48_1
e_1_2_10_67_1
e_1_2_10_24_1
e_1_2_10_45_1
e_1_2_10_22_1
e_1_2_10_43_1
e_1_2_10_20_1
Go C. C. (e_1_2_10_27_1) 2020
e_1_2_10_41_1
e_1_2_10_71_1
e_1_2_10_1_1
e_1_2_10_73_1
e_1_2_10_52_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_75_1
e_1_2_10_54_1
Djupesland P. G. (e_1_2_10_56_1) 2020
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_38_1
e_1_2_10_77_1
e_1_2_10_79_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_36_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
Rowe R. C. (e_1_2_10_49_1) 2012
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_31_1
e_1_2_10_50_1
Kulkarni V. (e_1_2_10_59_1) 2012
e_1_2_10_60_1
e_1_2_10_81_1
e_1_2_10_62_1
e_1_2_10_83_1
e_1_2_10_64_1
e_1_2_10_28_1
e_1_2_10_47_1
e_1_2_10_68_1
References_xml – volume: 112
  start-page: 649
  year: 2022
  publication-title: Appl. Math. Model.
– volume: 24
  year: 2023
  publication-title: Int. J. Mol. Sci.
– start-page: 247
  year: 2010
  end-page: 290
– volume: 373
  start-page: 1979
  year: 2021
  publication-title: Science
– volume: 22
  year: 2021
  publication-title: Int. J. Mol. Sci.
– volume: 12
  year: 2020
  publication-title: Polymers (Basel)
– volume: 15
  year: 2019
  publication-title: PLoS Pathog.
– volume: 595
  start-page: 718
  year: 2021
  publication-title: Nature
– volume: 102
  start-page: 1788
  year: 2014
  publication-title: J. Biomed. Mater. Res A
– volume: 7
  year: 2012
  publication-title: PLoS One
– volume: 182
  start-page: 429
  year: 2020
  publication-title: Cell
– volume: 121
  year: 2017
  publication-title: J. Phys. Chem. C
– volume: 5
  year: 2022
  publication-title: JAMA Netw. Open
– volume: 10
  year: 2014
  publication-title: PLoS Pathog.
– volume: 3
  year: 2021
  publication-title: Front Med Technol
– volume: 11
  start-page: 404
  year: 2014
  publication-title: Ann. Am. Thorac. Soc.
– volume: 14
  start-page: 530
  year: 2022
  publication-title: Pharmaceutics
– volume: 10
  start-page: 140
  year: 2020
  publication-title: Reviews and Advances in Chemistry
– volume: 402
  start-page: 89
  year: 2010
  publication-title: Int. J. Pharm.
– volume: 2
  year: 2021
  publication-title: Commun Mater
– volume: 105
  start-page: 1209
  year: 2016
  publication-title: J. Pharm. Sci.
– volume: 48
  start-page: 1237
  year: 1996
  publication-title: J. Pharm. Pharmacol.
– start-page: 485
  year: 2020
  end-page: 495
– volume: 22
  start-page: 1293
  year: 2022
  publication-title: Lancet Infect. Dis.
– volume: 20
  year: 2020
  publication-title: BMC Pulm Med
– volume: 33
  year: 2021
  publication-title: Adv. Mater.
– volume: 2
  start-page: 105
  year: 1990
  publication-title: Acta Pharm. Nord.
– volume: 1
  year: 2020
  publication-title: VIEW
– volume: 2
  start-page: 571
  year: 2022
  publication-title: Immuno
– volume: 9
  start-page: 2
  year: 2023
  publication-title: Cell Discov.
– volume: 14
  start-page: 6277
  year: 2021
  publication-title: Int. J. Gen. Med.
– volume: 130
  start-page: 131
  year: 2004
  publication-title: Otolaryngol. – Head Neck Surg.
– volume: 11
  year: 2020
  publication-title: Nat. Commun.
– volume: 34
  start-page: 923
  year: 2008
  publication-title: Drug Dev. Ind. Pharm.
– volume: 89
  start-page: 11
  year: 1949
  publication-title: J. Exp. Med.
– volume: 16
  year: 2021
  publication-title: PLoS One
– volume: 43
  start-page: 932
  year: 2023
  publication-title: Med. Res. Rev.
– volume: 8
  year: 2021
  publication-title: Adv. Sci.
– volume: 21
  start-page: 62
  year: 2014
  publication-title: Drug Deliv
– volume: 155
  year: 2022
  publication-title: Journal of Clinical Virology
– volume: 388
  start-page: 125
  year: 2014
  publication-title: Carbohydr. Res.
– volume: 38
  start-page: 497
  year: 2015
  publication-title: Biol. Pharm. Bull
– volume: 5
  year: 2010
  publication-title: PLoS One
– volume: 131
  year: 2021
  publication-title: J. Clin. Invest.
– volume: 320
  start-page: L750
  year: 2021
  publication-title: Am. J .Physiol. Lung Cell Mol. Physiol.
– volume: 602
  start-page: 671
  year: 2022
  publication-title: Nature
– volume: 20
  start-page: 635
  year: 2021
  publication-title: Expert Rev. Vaccines
– volume: 8
  start-page: 111
  year: 2021
  publication-title: AIMS Biophys.
– volume: 6
  start-page: 99
  year: 2013
  publication-title: Sterile Product Development
– volume: 2
  start-page: 907
  year: 2001
  publication-title: Nat. Immunol.
– volume: 17
  start-page: 5
  year: 2020
  publication-title: Part. Fibre Toxicol.
– volume: 11
  year: 2021
  publication-title: Sci. Rep.
– volume: 26
  start-page: 681
  year: 2020
  publication-title: Nat. Med.
– volume: 16
  start-page: 355
  year: 2018
  publication-title: Nat. Rev. Microbiol.
– volume: 39
  start-page: 966
  year: 1987
  publication-title: J. Pharm. Pharmacol.
– volume: 2
  year: 2022
  publication-title: Exploration
– volume: 12
  year: 2021
  publication-title: Clin. Epidemiol. Glob. Health
– volume: 11
  start-page: 306
  year: 2019
  publication-title: Allergy Asthma Immunol. Res.
– volume: 26
  start-page: 975
  year: 2000
  publication-title: Drug Dev. Ind. Pharm.
– volume: 27
  start-page: 591
  year: 2021
  publication-title: Nat. Med.
– volume: 22
  start-page: 903
  year: 2023
  publication-title: Nat. Mater.
– volume: 385
  start-page: 320
  year: 2021
  publication-title: N. Engl. J. Med.
– year: 2020
  publication-title: Cureus
– volume: 191
  year: 2022
  publication-title: J. Supercrit. Fluids
– volume: 12
  year: 2022
  publication-title: BMJ Open
– year: 2012
– volume: 8
  year: 2020
  publication-title: Front. Bioeng. Biotechnol.
– year: 2022
  publication-title: Preprint, Research Square
– volume: 119
  year: 2022
  publication-title: Proc Natl Acad Sci U S A
– year: 2020
  publication-title: bioRxiv preprint
– volume: 84
  start-page: 8607
  year: 2010
  publication-title: J. Virol.
– volume: 1522
  start-page: 17
  year: 2017
  publication-title: Methods Mol. Biol.
– volume: 481
  start-page: 107
  year: 2015
  publication-title: Virology
– volume: 146
  start-page: 1054
  year: 2020
  publication-title: JAMA Otolaryngol. Head Neck Surg.
– volume: 3
  year: 2022
  publication-title: Lancet Region. Health – Southeast Asia
– volume: 6
  year: 2011
  publication-title: PLoS One
– year: 2012
  publication-title: Formulat. Characteriz. Nasal Sprays
– volume: 323
  start-page: 2386
  year: 2020
  publication-title: JAMA – J. Am. Med. Assoc.
– volume: 32
  year: 2020
  publication-title: Cell Rep.
– volume: 67
  start-page: 132
  year: 2007
  publication-title: Eur. J. Pharm. Biopharm.
– volume: 76
  year: 2023
  publication-title: Clin. Infect. Dis.
– volume: 163
  start-page: 244
  year: 2008
  publication-title: Respir. Physiol. Neurobiol.
– volume: 132
  start-page: 2089
  year: 2022
  publication-title: Laryngoscope
– volume: 7
  year: 2022
  publication-title: Sci Immunol
– ident: e_1_2_10_78_1
  doi: 10.3109/10717544.2013.849778
– ident: e_1_2_10_3_1
  doi: 10.1038/s41591-021-01301-0
– year: 2012
  ident: e_1_2_10_59_1
  publication-title: Formulat. Characteriz. Nasal Sprays
– ident: e_1_2_10_9_1
  doi: 10.1172/JCI148517
– ident: e_1_2_10_18_1
  doi: 10.1371/journal.pone.0237480
– ident: e_1_2_10_64_1
  doi: 10.1002/med.21941
– ident: e_1_2_10_38_1
  doi: 10.3390/polym12020329
– ident: e_1_2_10_17_1
  doi: 10.1136/bmjopen-2021-059661
– year: 2020
  ident: e_1_2_10_66_1
  publication-title: bioRxiv preprint
– ident: e_1_2_10_29_1
  doi: 10.1002/advs.202003895
– year: 2020
  ident: e_1_2_10_27_1
  publication-title: Cureus
– ident: e_1_2_10_67_1
  doi: 10.1134/S207997802003005X
– ident: e_1_2_10_65_1
  doi: 10.1038/s41586-021-04389-z
– ident: e_1_2_10_13_1
  doi: 10.1038/s41421-022-00510-2
– ident: e_1_2_10_81_1
  doi: 10.1016/j.ijpharm.2010.09.028
– volume: 373
  start-page: 1979
  year: 2021
  ident: e_1_2_10_8_1
  publication-title: Science
– ident: e_1_2_10_83_1
  doi: 10.1016/B978-0-8155-2025-2.10010-1
– ident: e_1_2_10_10_1
  doi: 10.1038/s41591-020-0868-6
– ident: e_1_2_10_40_1
  doi: 10.3389/fmedt.2021.687681
– ident: e_1_2_10_15_1
  doi: 10.1038/s41579-018-0001-8
– ident: e_1_2_10_31_1
  doi: 10.1080/03639040802149046
– ident: e_1_2_10_23_1
  doi: 10.1016/j.jcv.2022.105248
– ident: e_1_2_10_77_1
  doi: 10.1038/s41563-023-01475-7
– ident: e_1_2_10_21_1
  doi: 10.1371/journal.pone.0014320
– ident: e_1_2_10_62_1
  doi: 10.1016/j.celrep.2020.108062
– ident: e_1_2_10_28_1
  doi: 10.1002/adma.202008304
– ident: e_1_2_10_16_1
  doi: 10.3390/pharmaceutics14030530
– ident: e_1_2_10_36_1
  doi: 10.1016/j.supflu.2022.105762
– ident: e_1_2_10_63_1
  doi: 10.1038/s41598-021-99765-0
– ident: e_1_2_10_61_1
  doi: 10.1371/journal.ppat.1008098
– ident: e_1_2_10_14_1
  doi: 10.1371/journal.ppat.1004089
– ident: e_1_2_10_42_1
  doi: 10.1084/jem.89.1.11
– ident: e_1_2_10_45_1
  doi: 10.3934/biophy.2021008
– ident: e_1_2_10_52_1
  doi: 10.1111/j.2042-7158.1987.tb03142.x
– ident: e_1_2_10_84_1
  doi: 10.1186/s12890-020-01187-7
– ident: e_1_2_10_50_1
  doi: 10.3390/ijms241512132
– ident: e_1_2_10_44_1
  doi: 10.1371/journal.pone.0040422
– ident: e_1_2_10_22_1
  doi: 10.1093/cid/ciac448
– ident: e_1_2_10_32_1
  doi: 10.1081/DDC-100101325
– ident: e_1_2_10_82_1
  doi: 10.1007/978-1-4939-6591-5_2
– ident: e_1_2_10_46_1
  doi: 10.2147/IJGM.S328486
– ident: e_1_2_10_12_1
  doi: 10.1016/j.cell.2020.05.042
– volume: 2
  start-page: 105
  year: 1990
  ident: e_1_2_10_76_1
  publication-title: Acta Pharm. Nord.
– ident: e_1_2_10_57_1
  doi: 10.1248/bpb.b14-00398
– ident: e_1_2_10_2_1
  doi: 10.1080/14760584.2021.1915140
– ident: e_1_2_10_48_1
  doi: 10.1111/j.2042-7158.1996.tb03929.x
– ident: e_1_2_10_25_1
  doi: 10.3390/ijms222413202
– ident: e_1_2_10_72_1
  doi: 10.1073/pnas.2202069119
– ident: e_1_2_10_79_1
  doi: 10.1002/jbm.a.34851
– ident: e_1_2_10_73_1
  doi: 10.1128/JVI.00159-10
– volume-title: Handbook of Pharmaceutical Excipients
  year: 2012
  ident: e_1_2_10_49_1
– ident: e_1_2_10_55_1
  doi: 10.1016/j.otohns.2003.07.005
– ident: e_1_2_10_74_1
  doi: 10.1016/j.virol.2015.02.041
– start-page: 485
  volume-title: Ther Deliv
  year: 2020
  ident: e_1_2_10_56_1
– ident: e_1_2_10_6_1
  doi: 10.3390/immuno2040036
– ident: e_1_2_10_11_1
  doi: 10.1001/jama.2020.8946
– ident: e_1_2_10_20_1
  doi: 10.1016/j.lansea.2022.100036
– ident: e_1_2_10_60_1
  doi: 10.1371/journal.pone.0021207
– ident: e_1_2_10_5_1
  doi: 10.1016/S1473-3099(22)00320-6
– volume: 11
  year: 2020
  ident: e_1_2_10_80_1
  publication-title: Nat. Commun.
– ident: e_1_2_10_19_1
  doi: 10.1001/jamaoto.2020.3053
– year: 2022
  ident: e_1_2_10_26_1
  publication-title: Preprint, Research Square
– ident: e_1_2_10_7_1
  doi: 10.1056/NEJMoa2107058
– ident: e_1_2_10_54_1
  doi: 10.1186/s12989-020-0339-8
– ident: e_1_2_10_30_1
  doi: 10.1002/lary.29935
– ident: e_1_2_10_24_1
  doi: 10.1002/EXP.20210038
– ident: e_1_2_10_75_1
  doi: 10.1126/sciimmunol.abl9929
– ident: e_1_2_10_58_1
  doi: 10.1007/978-1-4614-7978-9_5
– ident: e_1_2_10_4_1
  doi: 10.1001/jamanetworkopen.2022.6108
– ident: e_1_2_10_35_1
  doi: 10.1152/ajplung.00552.2020
– ident: e_1_2_10_41_1
  doi: 10.1038/s43246-021-00153-y
– ident: e_1_2_10_47_1
  doi: 10.1016/j.cegh.2021.100826
– ident: e_1_2_10_69_1
  doi: 10.4168/aair.2019.11.3.306
– ident: e_1_2_10_70_1
  doi: 10.1038/s41586-021-03673-2
– ident: e_1_2_10_34_1
  doi: 10.1016/j.carres.2014.02.018
– ident: e_1_2_10_53_1
  doi: 10.3389/fbioe.2020.581995
– ident: e_1_2_10_37_1
  doi: 10.1021/acs.jpcc.7b03885
– ident: e_1_2_10_1_1
  doi: 10.1513/AnnalsATS.201311-405PS
– ident: e_1_2_10_33_1
  doi: 10.1016/j.xphs.2015.12.016
– ident: e_1_2_10_39_1
  doi: 10.1016/j.apm.2022.08.008
– ident: e_1_2_10_68_1
  doi: 10.1016/j.ejpb.2007.01.010
– ident: e_1_2_10_43_1
  doi: 10.1002/viw2.16
– ident: e_1_2_10_51_1
  doi: 10.1016/j.resp.2008.05.018
– ident: e_1_2_10_71_1
  doi: 10.1038/ni1001-907
SSID ssj0009606
Score 2.468977
Snippet Nasal sprays for pre‐exposure prophylaxis against respiratory infections show limited protection (20–70%), largely due to their single mechanism of...
Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage e2406348
SubjectTerms Administration, Intranasal
Animals
antibacterial
antiviral
Barriers
broad spectrum protection
Disease Models, Animal
Droplets
Effectiveness
Infections
Mice
nasal prophylaxis
nasal spray
Nasal Sprays
Neutralizing
Orthomyxoviridae Infections - prevention & control
pathogen capture
Pathogens
Prophylaxis
respiratory infections
Respiratory Tract Infections - prevention & control
Respiratory Tract Infections - virology
virus neutralization
Title Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadma.202406348
https://www.ncbi.nlm.nih.gov/pubmed/39318086
https://www.proquest.com/docview/3128450802
https://www.proquest.com/docview/3109421810
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT4QwEJ4YT3rw_cBXamLiCcUWKBw3PqIm62HVRE9kKK0xGta4uwc9-RP8jf4SO2VhXT2Y6IVASqF0Osw37cxXgB3MY6ETpXwVGu2HFiL7Kc-1L_LE8EAhpoamBtoX8el1eH4T3XzJ4q_4IZoJN9IM978mBce8tz8iDcXC8QaRRRIhZftSwBahos6IP4rguSPbE5GfxmFSszYGfH-8-rhV-gE1x5GrMz0ns4B1o6uIk4e9QT_fU6_f-Bz_81VzMDPEpaxVDaR5mNDlAkx_YStchNsrF2LLkHXQre48vrDLe2IXZi6N9-Ptvd0t7EMusGePl0_P-MIsJmY1TVR5xzqjlX12NowDK3tLcH1yfHV46g93ZvCV4Fa1jBBKSoFEJm_9N2l4XkQyNCmqQlqNLw6QK6MwKFSqUMXGhLRHVmR9R23LpFiGybJb6lVgkhuiqMt1EqcWLcikwNBgoLX1o1IVSw92a8lkTxUBR1ZRLfOMOitrOsuDjVpw2VARe5kg-xtRQrEH202xVSFaF8FSdwd0j_VxCeoEHqxUAm9eJVL707Nunwfcie2XNmSto3aruVr7S6V1mKLzKt9xAyb7zwO9aYFPP99yg_sTMOT6wA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB71caAcoEALabdgpEqcsg12EifHFbDatps97EMqp8hxbIRA2dU-DuXUn9Df2F9Sj_NYthwqlUukxHHieDyZb-yZzwCnIguZiqR0pa-V6xuI7MY0Uy7LIk09KUSscWogGYS9iX9xFdTRhJgLU_JDNBNuqBn2f40KjhPSZ2vWUJFb4iA0ScyPtmEXt_W2XtVwzSCFAN3S7bHAjUM_qnkbPXq2WX_TLv0DNjexqzU-3ZeQ1c0uY05-tVfLrC3_PGB0_K_v2ocXFTQlnXIsvYItVbyG538RFr6B72MbZUsEGQq7wPP7mox-IsEwsZm8dze3yTQ3DxmIhTmOZnNxTQwsJjVTVPGDDNeL--S8CgUrFgcw6X4bf-m51eYMrmTUaJdmTHLOBPLJGxeOa5rlAfd1LGTOjdLnnwWVWgovl7EUMtTax22yAuM-KlPG2SHsFNNCvQPCqUaWukxFYWwAA49y4WvhKWVcqViG3IFPtWjSWcnBkZZsyzTFzkqbznKgVUsurXRxkTI0wQHmFDvwsSk2WoRLI6JQ0xXeY9xcRDueA29LiTevYrH57xnPzwFq5fZIG9LO16TTnB09pdIHeNYbJ_20fz64PIY9vF6mP7ZgZzlfqRODg5bZezvS7wHhxP7b
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BkRAcyj9NKWAkJE5pUzuJk-OKZdUCu0LbViqnaOLYqAJlV93dQznxCH1GnoQZZ5Pt0gNSuURKHMeOx-P5xvZ8BniLZapsZkxoYmfDmCBymMvShqrMnIwMYu54amA4Sg9O4o-nyemVKP6GH6KbcGPN8OM1K_i0cnsr0lCsPG8QWyQVZ7fhDhWUcb_uj1cEUozPPdueSsI8jbOWtjGSe-v5183SNay5Dl297Rk8AGxr3Ww5-b67mJe75udfhI7_81sPYXMJTEWv6UmP4JatH8P9K3SFT-Drsd9jK1CM0S_v_LgQR2dMLyx8HO_vX5fDSUUfGeGMrkfTc7wQBIpFyxNVfxPj1dK-OFxuBKtnT-Fk8OH4_UG4PJohNEqSbjmljNYKmU2eHDjtZFklOnY5mkqTylf7KI0zGFUmN2hS52I-JCsh59FSmlbPYKOe1HYLhJaOOepKm6U5wQWdVRg7jKwlRyo3qQ7gXSuZYtowcBQN17IsuLGKrrEC2GkFVyw1cVYoNsAJRxQH8KZLJh3ihRGs7WTB75CTy1gnCuB5I_CuKJXTqEd-XwDSi-0fdSh6_WGvu9u-SabXcPdLf1B8Phx9egH3-HET-7gDG_PzhX1JIGhevvL9_A_8g_2T
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toward+a+Radically+Simple+Multi%E2%80%90Modal+Nasal+Spray+for+Preventing+Respiratory+Infections&rft.jtitle=Advanced+materials+%28Weinheim%29&rft.au=Joseph%2C+John&rft.au=Helna%2C+Mary+Baby&rft.au=Joselyn+Rojas+Quintero&rft.au=Kenney%2C+Devin&rft.date=2024-11-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0935-9648&rft.eissn=1521-4095&rft.volume=36&rft.issue=46&rft_id=info:doi/10.1002%2Fadma.202406348&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0935-9648&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0935-9648&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0935-9648&client=summon